ECSP982523A - SAL TARTRATO OF A SUBSTITUTED DIPEPTIDE - Google Patents
SAL TARTRATO OF A SUBSTITUTED DIPEPTIDEInfo
- Publication number
- ECSP982523A ECSP982523A ECSP982523A ECSP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- tartaric acid
- useful
- acid salt
- osteoporosis
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere a la sal de ácido (L)-tartárico o de la 2-amino-N-{1-2,4-difluoro-benciloximetil)-2-oxo-2- [3-oxo-3a-piridin -2-ilmetil-2-(2,2,2-trifluoro-etil)-2,3,3aA, 6,7-hexahidro-pirazolo [4,3-c] piridin -5-il] etil}-2-metil-propionamida, la cual es un secretagogo de la hormona de crecimiento endógena. En otro aspecto, esta invención proporciona determinados productos intermedios que son útiles para la síntesis del compuesto anterior. La sal del ácido (L)-tartárico del compuesto de está invención es útil para el tratamiento y/o prevención de la osteoporosis, resistencia a la insulina y otros trastornos o enfermedades asociadas con la diferencia de hormona del crecimiento. La sal del ácido (L)-tartárico del compuesto de la presente invención es también útil para el tratamiento de la osteoporosis cuando se usa en combinación con: un compuesto bisfosfonato, estrógenos, Premarin y opcionalmente progesterona, un agonista o antagonista de estrógenos o calcitonina. Además,la presente invención se refiere a procedimientos que comprenden la administración de un agonista alfa-2-adrenérgico y de la sal del ácido (L)-tartárico del compuesto de esta invención.This invention relates to the (L) -tartaric acid or 2-amino-N- {1-2,4-difluoro-benzyloxymethyl) -2-oxo-2- [3-oxo-3a-pyridin - salt. 2-ylmethyl-2- (2,2,2-trifluoro-ethyl) -2,3,3aA, 6,7-hexahydro-pyrazolo [4,3-c] pyridin -5-yl] ethyl} -2-methyl -propionamide, which is a secretagogue of endogenous growth hormone. In another aspect, this invention provides certain intermediates that are useful for the synthesis of the above compound. The (L) -tartaric acid salt of the compound of this invention is useful for the treatment and / or prevention of osteoporosis, insulin resistance and other disorders or diseases associated with growth hormone difference. The (L) -tartaric acid salt of the compound of the present invention is also useful for the treatment of osteoporosis when used in combination with: a bisphosphonate compound, estrogens, Premarin and optionally progesterone, an estrogen agonist or antagonist or calcitonin . Furthermore, the present invention relates to processes comprising the administration of an alpha-2-adrenergic agonist and the (L) -tartaric acid salt of the compound of this invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982523 ECSP982523A (en) | 1998-06-08 | 1998-06-08 | SAL TARTRATO OF A SUBSTITUTED DIPEPTIDE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982523 ECSP982523A (en) | 1998-06-08 | 1998-06-08 | SAL TARTRATO OF A SUBSTITUTED DIPEPTIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982523A true ECSP982523A (en) | 1999-01-26 |
Family
ID=42043444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982523 ECSP982523A (en) | 1998-06-08 | 1998-06-08 | SAL TARTRATO OF A SUBSTITUTED DIPEPTIDE |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982523A (en) |
-
1998
- 1998-06-08 EC ECSP982523 patent/ECSP982523A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4810383A1 (en) | SAL TARTRATO OF A SUBSTITUTED DIPEPTIDE | |
| Mohan et al. | Comparison of bone formation responses to parathyroid hormone (1-34),(1-31), and (2-34) in mice | |
| US8076316B2 (en) | Steroid compounds and formulations | |
| JP4486258B2 (en) | Modification, preparation and use of human parathyroid hormone | |
| JP2632754B2 (en) | Brain glutamate release inhibitor | |
| Gozes et al. | Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment | |
| US7521528B2 (en) | Conformationally constrained parathyroid hormone (PTH) analogs with lactam bridges | |
| HU213098B (en) | Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components | |
| EP0748817A3 (en) | Parathyroid hormone derivatives and their use | |
| HUP0001922A2 (en) | Pyrazolo[4,3-c]-pyridine derivatives, pharmaceutical compositions thereof against insulin resistance, intermediates and process for their preparation | |
| US7910544B2 (en) | Conformationally constrained parthyroid hormone (PTH) analogs | |
| US7799757B2 (en) | Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents | |
| BR0100946A (en) | Hexahydropyrazolo [4,3-c] pyridine metabolites | |
| JP2002060348A (en) | Use of growth hormone secretagogue for treatment of physical performance decline | |
| KLEIN-NULEND et al. | Comparison of the Effects of Synthetic Human Parathyroid Hormone (PTH)-(l–34)-Related Peptide of Malignancy and Bovine PTH-(l–34) on Bone Formation and Resorption in Organ Culture | |
| ECSP982523A (en) | SAL TARTRATO OF A SUBSTITUTED DIPEPTIDE | |
| Horiuchi et al. | A multiresponse parathyroid hormone assay: An inhibitor has agonist properties in vivo | |
| KR970004039B1 (en) | Cyclopeptides as absorption enhancers for administration on the mucous membranes | |
| Klein et al. | Parathyroid hormone-like adenylate cyclase-stimulating activity from a human carcinoma is associated with bone-resorbing activity | |
| Friderichs et al. | Activity of thyroliberin analogs with a modified pyroglutamyl residue on the central nervous system | |
| Saggese et al. | Combined treatment with growth hormone and gonadotropin-releasing hormone analogues in children with isolated growth hormone deficiency | |
| Pintor et al. | Synthetic hpGRF 1–40 stimulates growth hormone and inhibits prolactin secretion in normal children and children with isolated growth hormone deficiency | |
| Escobar et al. | Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome | |
| Horiuchi et al. | Evaluation of a parathyroid hormone antagonist in an in vivo multiparameter bioassay | |
| Dresner‐Pollak et al. | Evaluation in vivo of a potent parathyroid hormone antagonist:[Nle8, 18, D‐Trp12, Tyr34] bPTH (7–34) NH2 |